{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:49:10Z","timestamp":1791413350435,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["24616"],"award-info":[{"award-number":["24616"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Sex Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits well-established sex differences across its risk factors, disease progression, and liver-related and extrahepatic outcomes. We trained sex-specific machine learning (ML) algorithms using routine clinical data to evaluate sex-specific learning patterns and diagnostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study conducted at a cardiology referral center, 446 adults were enrolled. Participants were divided into training (127 men, 185 women) and test sets (55 men, 79 women). Eight ML classifiers were trained on the overall dataset and separately for men and women to predict MASLD presence and steatosis severity (no\/mild\/moderate-to-severe) as assessed by ultrasonography. Hyperparameters were tuned using grid search cross-validation, and model performance was evaluated on an unseen test set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of MASLD was 63.6% among participants; 41.2% had mild, and 22.4% had moderate-to-severe steatosis. Compared to models trained on the overall dataset, sex-specific modeling improved diagnostic performance in men but remained suboptimal in women. For MASLD presence, top-performing models achieved AUC\/F1 scores of 0.769\/0.856 overall, 0.793\/0.897 in men, and 0.681\/0.794 in women. For steatosis severity, respective AUC\/F1 scores were 0.761\/0.671 overall, 0.723\/0.608 in men, and 0.718\/0.571 in women. Sensitivity analyses using stratified cross-validation confirmed the performance gap between men and women. Threshold analyses showed acceptable rule-in and rule-out performance in men but suboptimal performance in women. Feature-importance rankings differed substantially between sexes, indicating distinct sex-specific learning patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Artificial intelligence-based algorithms identify sex-specific learning patterns in MASLD steatosis risk prediction. Routine clinical variables appear more informative for men, while showing weaker algorithmic performance in women. This finding suggests that failure to train MASLD risk algorithms with sex-specific risk factors may increase the risk of misclassification in women. Therefore, achieving more equitable and clinically reliable models will require integrating women-specific risk factors and adopting sex-stratified data processing strategies within MASLD prediction frameworks to reduce diagnostic inequities and support more personalized care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13293-026-00917-6","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:12:46Z","timestamp":1778242366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Artificial intelligence predicts sex-specific risk of metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Mohamad","family":"Jamalinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Lonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Taghi","family":"Heydari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Bagheri Lankarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"6","key":"917_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol. 2023;78(6):1966\u201386. https:\/\/doi.org\/10.1097\/hep.0000000000000520.","journal-title":"Hepatol"},{"issue":"7","key":"917_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"917_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32-s50. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"key":"917_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","author":"H Tilg","year":"2025","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.19615.","journal-title":"JAMA"},{"issue":"4","key":"917_CR5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s12325-025-03121-x","volume":"42","author":"K Bagheri Lankarani","year":"2025","unstructured":"Bagheri Lankarani K, Jamalinia M, Zare F, Heydari ST, Ardekani A, Lonardo A. Liver-kidney-metabolic health, sex, and menopause impact total scores and monovessel vs. multivessel coronary artery calcification. Adv Ther. 2025;42(4):1729\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03121-x.","journal-title":"Adv Ther"},{"issue":"4","key":"917_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/apt.17869","volume":"59","author":"M Jamalinia","year":"2024","unstructured":"Jamalinia M, Zare F, Noorizadeh K, Bagheri Lankarani K. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(4):445\u201358. https:\/\/doi.org\/10.1111\/apt.17869.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"917_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41575-025-01048-w","volume":"22","author":"N Stefan","year":"2025","unstructured":"Stefan N, Targher G. Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat Rev Gastroenterol Hepatol. 2025;22(4):226\u20137. https:\/\/doi.org\/10.1038\/s41575-025-01048-w.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"917_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.20517\/mtod.2025.193","volume":"6","author":"A Lonardo","year":"2026","unstructured":"Lonardo A, Jamalinia M, Weiskirchen R. Biological determinants and outcomes of sex discrepancies in MASLD. Metab Target Organ Damage. 2026;6(1):4.","journal-title":"Metab Target Organ Damage"},{"issue":"10","key":"917_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.tem.2023.07.003","volume":"34","author":"CB Wiese","year":"2023","unstructured":"Wiese CB, Avetisyan R, Reue K. The impact of chromosomal sex on cardiometabolic health and disease. Trends Endocrinol Metab. 2023;34(10):652\u201365. https:\/\/doi.org\/10.1016\/j.tem.2023.07.003.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"917_CR10","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.3390\/cimb45100496","volume":"45","author":"T Ciarambino","year":"2023","unstructured":"Ciarambino T, Crispino P, Guarisco G, Giordano M. Gender differences in insulin resistance: new knowledge and perspectives. Curr Issues Mol Biol. 2023;45(10):7845\u201361. https:\/\/doi.org\/10.3390\/cimb45100496.","journal-title":"Curr Issues Mol Biol"},{"key":"917_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092292","author":"I Milani","year":"2025","unstructured":"Milani I, Parrotta ME, Colangeli L, Chinucci M, Palleschi S, Rossi B, et al. Sex differences in MASLD after age 50: Presentation, diagnosis, and clinical implications. Biomed. 2025. https:\/\/doi.org\/10.3390\/biomedicines13092292.","journal-title":"Biomed"},{"issue":"9","key":"917_CR12","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1111\/dom.16568","volume":"27","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis. Diabetes Obes Metab. 2025;27(9):5171\u201381. https:\/\/doi.org\/10.1111\/dom.16568.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"917_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48946","volume":"7","author":"T Yan","year":"2024","unstructured":"Yan T, Zhang X, Wong T, Cheung R, Nguyen MH. Sex differences in adverse liver and nonliver outcomes in steatotic liver disease. JAMA Netw Open. 2024;7(12):e2448946. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.48946.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"917_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","volume":"11","author":"EM Koehler","year":"2013","unstructured":"Koehler EM, Schouten JNL, Hansen BE, Hofman A, Stricker BH, Janssen HLA. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201\u20134. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.031.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"917_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.11.049","volume":"82","author":"P Cal\u00e8s","year":"2025","unstructured":"Cal\u00e8s P, Canivet CM, Costentin C, Lannes A, Oberti F, Fouchard I, et al. A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol. 2025;82(5):794\u2013804. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.049.","journal-title":"J Hepatol"},{"issue":"1","key":"917_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-024-00617-z","volume":"15","author":"L Crudele","year":"2024","unstructured":"Crudele L, De Matteis C, Novielli F, Di Buduo E, Petruzzelli S, De Giorgi A, et al. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol Sex Differ. 2024;15(1):43. https:\/\/doi.org\/10.1186\/s13293-024-00617-z.","journal-title":"Biol Sex Differ"},{"issue":"1","key":"917_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5009\/gnl240302","volume":"19","author":"S Narayanasamy","year":"2025","unstructured":"Narayanasamy S, Franca M, Idilman IS, Yin M, Venkatesh SK. Advanced imaging techniques for assessing fat, iron, and fibrosis in chronic liver disease. Gut Liver. 2025;19(1):31\u201342. https:\/\/doi.org\/10.5009\/gnl240302.","journal-title":"Gut Liver"},{"issue":"8","key":"917_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330899","volume":"20","author":"W El Atifi","year":"2025","unstructured":"El Atifi W, El Rhazouani O, Khan FM, Sekkat H. Optimizing ensemble machine learning models for accurate liver disease prediction in healthcare. PLoS ONE. 2025;20(8):e0330899. https:\/\/doi.org\/10.1371\/journal.pone.0330899.","journal-title":"PLoS ONE"},{"issue":"1","key":"917_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06387-5","volume":"23","author":"G Zhu","year":"2025","unstructured":"Zhu G, Song Y, Lu Z, Yi Q, Xu R, Xie Y, et al. Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics. J Transl Med. 2025;23(1):381. https:\/\/doi.org\/10.1186\/s12967-025-06387-5.","journal-title":"J Transl Med"},{"issue":"10250","key":"917_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(20)31561-0","volume":"396","author":"F Mauvais-Jarvis","year":"2020","unstructured":"Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396(10250):565\u201382. https:\/\/doi.org\/10.1016\/s0140-6736(20)31561-0.","journal-title":"Lancet"},{"issue":"8","key":"917_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.Mss.0000078924.61453.Fb","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sj\u00f6str\u00f6m M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381\u201395. https:\/\/doi.org\/10.1249\/01.Mss.0000078924.61453.Fb.","journal-title":"Med Sci Sports Exerc"},{"issue":"9","key":"917_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"8","key":"917_CR23","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/s2214-109x(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027\u201337. https:\/\/doi.org\/10.1016\/s2214-109x(20)30215-1.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"917_CR24","first-page":"7","volume":"1","author":"S Ballestri","year":"2021","unstructured":"Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage. 2021;1(1):7.","journal-title":"Metab Target Organ Damage"},{"key":"917_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101037","author":"JG Regensteiner","year":"2025","unstructured":"Regensteiner JG, McNeil M, Faubion SS, Bairey-Merz CN, Gulati M, Joffe H, et al. Barriers and solutions in women\u2019s health research and clinical care: A call to action. Lancet Reg Health Am. 2025. https:\/\/doi.org\/10.1016\/j.lana.2025.101037.","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"917_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","volume":"30","author":"A Cherubini","year":"2024","unstructured":"Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024;30(12):1126\u201336. https:\/\/doi.org\/10.1016\/j.molmed.2024.05.013.","journal-title":"Trends Mol Med"},{"issue":"1","key":"917_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2024.0419","volume":"31","author":"C Meda","year":"2025","unstructured":"Meda C, Dolce A, Della Torre S. Metabolic dysfunction-associated steatotic liver disease across women\u2019s reproductive lifespan and issues. Clin Mol Hepatol. 2025;31(1):327\u201332. https:\/\/doi.org\/10.3350\/cmh.2024.0419.","journal-title":"Clin Mol Hepatol"},{"key":"917_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1579453","volume":"12","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Li L, Wang C, Li S, Chen P, Huang J, et al. The association between sedentary behavior and MASLD in overweight and obese adults: investigating the role of inflammatory markers using NHANES data (2017-March 2020). Front Nutr. 2025;12:1579453. https:\/\/doi.org\/10.3389\/fnut.2025.1579453.","journal-title":"Front Nutr"},{"key":"917_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2025.01.030","volume":"134","author":"R Gualtierotti","year":"2025","unstructured":"Gualtierotti R. Bridging the gap: time to integrate sex and gender differences into research and clinical practice for improved health outcomes. Eur J Intern Med. 2025;134:9\u201316. https:\/\/doi.org\/10.1016\/j.ejim.2025.01.030.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"917_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjhci-2021-100457","volume":"29","author":"I Straw","year":"2022","unstructured":"Straw I, Wu H. Investigating for bias in healthcare algorithms: a sex-stratified analysis of supervised machine learning models in liver disease prediction. BMJ Health Care Inform. 2022;29(1):e100457. https:\/\/doi.org\/10.1136\/bmjhci-2021-100457.","journal-title":"BMJ Health Care Inform"},{"issue":"10","key":"917_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17474124.2025.2557243","volume":"19","author":"F Novielli","year":"2025","unstructured":"Novielli F, De Matteis C, Moschetta A, Crudele L. Non-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scores. Expert Rev Gastroenterol Hepatol. 2025;19(10):1081\u2013100. https:\/\/doi.org\/10.1080\/17474124.2025.2557243.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"917_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.20517\/mtod.2025.131","volume":"5","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia M, Saeian S, Nikkhoo N, Nazerian A, Lankarani KB. Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions. Metab Target Organ Damage. 2025;5(4):60. https:\/\/doi.org\/10.20517\/mtod.2025.131.","journal-title":"Metab Target Organ Damage"},{"key":"917_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101037","volume":"44","author":"JG Regensteiner","year":"2025","unstructured":"Regensteiner JG, McNeil M, Faubion SS, Bairey-Merz CN, Gulati M, Joffe H, et al. Barriers and solutions in women\u2019s health research and clinical care: a call to action. Lancet Reg Health Am. 2025;44:101037. https:\/\/doi.org\/10.1016\/j.lana.2025.101037.","journal-title":"Lancet Reg Health Am"},{"issue":"3","key":"917_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G, Targher G, Byrne CD, Yilmaz Y, Wong W-S, Lesmana ACR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7(3):101271. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101271.","journal-title":"JHEP Rep"},{"issue":"5","key":"917_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatol. 2015;61(5):1547\u201354. https:\/\/doi.org\/10.1002\/hep.27368.","journal-title":"Hepatol"},{"issue":"5","key":"917_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.005.","journal-title":"J Hepatol"}],"container-title":["Biology of Sex Differences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13293-026-00917-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-026-00917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-026-00917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:25:53Z","timestamp":1782887153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13293-026-00917-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1186\/s13293-026-00917-6","relation":{},"ISSN":["2042-6410"],"issn-type":[{"value":"2042-6410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and was approved by the Institutional Review Board of Shiraz University of Medical Sciences (SUMS) (approval number: IR.SUMS.REC.1401.042). Written informed consent was obtained from all patients before their enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}